AR046402A1 - Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio - Google Patents
Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasioInfo
- Publication number
- AR046402A1 AR046402A1 ARP040102607A ARP040102607A AR046402A1 AR 046402 A1 AR046402 A1 AR 046402A1 AR P040102607 A ARP040102607 A AR P040102607A AR P040102607 A ARP040102607 A AR P040102607A AR 046402 A1 AR046402 A1 AR 046402A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- active principle
- compound
- potassium channel
- dihydrobencenosulphonic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Combinación de principio activo que comprende al menos un compuesto 2,5-dihidroxibencenosulfónico y al menos un modulador de los canales de Potasio, un medicamento que comprende dicha combinación de principio activo, una formulación farmacéutica que comprende dicha combinación de principio activo y el uso de dicha combinación de principio activo para la fabricación de un medicamento. Para la profilaxis y/o tratamiento de disfunción sexual masculina, entre otras.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200301809A ES2222831B2 (es) | 2003-07-30 | 2003-07-30 | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046402A1 true AR046402A1 (es) | 2005-12-07 |
Family
ID=34130543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102607A AR046402A1 (es) | 2003-07-30 | 2004-07-22 | Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070032471A1 (es) |
EP (1) | EP1651204A1 (es) |
JP (1) | JP2007500163A (es) |
CN (1) | CN1826107A (es) |
AR (1) | AR046402A1 (es) |
CA (1) | CA2534097A1 (es) |
CL (1) | CL2004001843A1 (es) |
ES (1) | ES2222831B2 (es) |
MX (1) | MXPA06001139A (es) |
PE (1) | PE20050252A1 (es) |
TW (1) | TW200507838A (es) |
WO (1) | WO2005013962A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080125485A1 (en) | 2004-02-17 | 2008-05-29 | Action Medicines | Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis |
US20070149618A1 (en) | 2004-02-17 | 2007-06-28 | Action Medicines, S.L. | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis |
ES2238924B1 (es) | 2004-02-17 | 2006-12-01 | Investread Europa, S.L. | Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes. |
EP1676573A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor |
WO2008020039A2 (en) | 2006-08-16 | 2008-02-21 | Action Medicines, S.L. | 2,5-dihydroxybenzene compounds for treating cancers and hematological dyscrasias |
PT2056815E (pt) | 2006-08-16 | 2013-04-03 | Amderma Pharmaceuticals Llc | Utilização de derivados de 2,5-dihidroxibenzeno para tratar dermatite |
EP2056805B1 (en) * | 2006-08-16 | 2011-05-25 | Action Medicines, S.L. | Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases |
EP2313366A2 (en) | 2008-01-03 | 2011-04-27 | Action Medicines, S.L. | Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts |
US20100120906A1 (en) * | 2008-07-18 | 2010-05-13 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
WO2011089126A2 (en) * | 2010-01-20 | 2011-07-28 | Glaxo Group Limited | Novel composition |
CN104000792A (zh) * | 2014-04-15 | 2014-08-27 | 安徽万邦医药科技有限公司 | 一种瑞替加滨胃内漂浮型缓释片及其制备方法 |
WO2018157046A1 (en) * | 2017-02-24 | 2018-08-30 | Ovid Therapeutics Inc. | Methods of treating seizure disorders |
CN114601816B (zh) * | 2021-10-09 | 2022-09-02 | 北京惠之衡生物科技有限公司 | 一种羟苯磺酸钙胶囊组合物及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ239540A (en) * | 1990-09-24 | 1993-11-25 | Neurosearch As | 1-phenyl benzimidazole derivatives and medicaments |
JP2000508308A (ja) * | 1996-04-03 | 2000-07-04 | ラボラトリオス デル ドクトール エステベ,エス.アー. | 内皮機能の正常化、性的機能障害、糖尿病の血管合併症及び内皮起源の血管障害の治療用の医薬の製造のための2,5―ジヒドロキシベンゼンスルホン酸誘導体の使用 |
JP2003523965A (ja) * | 2000-01-26 | 2003-08-12 | シーダース シナイ メディカル センター | 異常な脳領域および/または悪性腫瘍に薬剤をデリバリーするためにカリウムチャンネルアゴニストを使用する方法 |
KR20010076961A (ko) * | 2000-01-29 | 2001-08-17 | 김제종 | 성기능장애 예방 및 치료용 약제 |
GB0021487D0 (en) * | 2000-09-01 | 2000-10-18 | Pfizer Ltd | Pharmaceutical |
ES2180446B1 (es) * | 2001-07-02 | 2004-01-16 | Esteve Labor Dr | Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. |
-
2003
- 2003-07-30 ES ES200301809A patent/ES2222831B2/es not_active Expired - Fee Related
-
2004
- 2004-07-22 AR ARP040102607A patent/AR046402A1/es unknown
- 2004-07-22 PE PE2004000694A patent/PE20050252A1/es not_active Application Discontinuation
- 2004-07-22 CL CL200401843A patent/CL2004001843A1/es unknown
- 2004-07-29 EP EP04763609A patent/EP1651204A1/en not_active Withdrawn
- 2004-07-29 TW TW093122678A patent/TW200507838A/zh unknown
- 2004-07-29 US US10/566,132 patent/US20070032471A1/en not_active Abandoned
- 2004-07-29 MX MXPA06001139A patent/MXPA06001139A/es not_active Application Discontinuation
- 2004-07-29 CN CNA2004800211261A patent/CN1826107A/zh active Pending
- 2004-07-29 JP JP2006521527A patent/JP2007500163A/ja active Pending
- 2004-07-29 CA CA002534097A patent/CA2534097A1/en not_active Abandoned
- 2004-07-29 WO PCT/EP2004/008509 patent/WO2005013962A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CL2004001843A1 (es) | 2005-05-20 |
ES2222831A1 (es) | 2005-02-01 |
ES2222831B2 (es) | 2006-02-16 |
MXPA06001139A (es) | 2006-04-24 |
CA2534097A1 (en) | 2005-02-17 |
WO2005013962A1 (en) | 2005-02-17 |
TW200507838A (en) | 2005-03-01 |
CN1826107A (zh) | 2006-08-30 |
PE20050252A1 (es) | 2005-06-12 |
JP2007500163A (ja) | 2007-01-11 |
EP1651204A1 (en) | 2006-05-03 |
US20070032471A1 (en) | 2007-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
AR037109A1 (es) | Uso de flibanserina | |
ES2156603T3 (es) | Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina. | |
HN2004000319A (es) | "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia" | |
CO5160262A1 (es) | Formulaciones farmaceuticas de liberacion controlada | |
AR109263A2 (es) | Composición que comprende moxidectina | |
AR021981A1 (es) | Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero | |
DK1689724T3 (da) | Quinazolinonforbindelser som anticancermidler | |
CR7140A (es) | Antranilamidas con una cadena colateral de un heteroarylsulfonil, metodos para la produccion de los mismos, su uso como medicamento o agente diagnostico y preparaciones farmaceuticas contenidas en dichos compuestos | |
AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
AR046402A1 (es) | Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio | |
NI200300042A (es) | Compuestos que modulan la actividad de ppar y metodos para su preparacion. | |
ES2088312T3 (es) | Formulacion de liberacion controlada que contiene tramadol. | |
AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
PA8502901A1 (es) | Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1 | |
AR052774A1 (es) | Inmunoterapia para trastornos autoinmunes | |
BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
CO5011053A1 (es) | Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento | |
UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
BRPI0414114A (pt) | uso de defibrotide, formulação, e, método para tratar um mamìfero afetado por um tumor | |
PA8549401A1 (es) | Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido | |
AR043327A1 (es) | Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes | |
BRPI0417265A (pt) | composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna | |
ES2150404T3 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |